stockrow
Saturday 7 November 2026
Export CCCC’s income statement to Excel — free account
C4 Therapeutics, Inc.
CCCC Healthcare Biotechnology
C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024.
- Revenue
- −24.6%
- EPS
- +63.6%
- Free cash flow
- +17.9%
Quarter to September 2026, against a year earlier
3.12
0.17
+5.76%
Follow CCCC
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
14.04 | 17.42 | 9.51 | 4.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(17.45) | (387.77) | (11.07) | (7.15) | |
P/B ratio |
1.99 | 2.47 | 1.42 | 0.62 | |
Price to Tangible BV |
1.99 | 2.47 | 1.42 | 0.62 | |
EV/Sales |
8.26 | 10.72 | 3.29 | (1.98) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.61 | |
EV/Operating CF |
(3.35) | (4.43) | (1.20) | 0.72 | |
EV/FCF |
(3.33) | (4.40) | (1.20) | 0.72 | |
Quick Ratio |
4.99 | 5.29 | 8.75 | 7.60 | |
Current Ratio |
5.17 | 5.45 | 9.00 | 7.81 | |
Net Debt/EBITDA |
0.00 | 9.64 | 8.28 | 10.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.11 | 0.11 | 0.10 | |
Operating CF/Net income |
1.19 | 0.07 | 1.19 | 1.08 | |
Capex/Depreciation |
— | (0.35) | 0.09 | 0.03 | |
Interest Coverage |
— | 9.48 | 10.46 | 4.61 | |
Research and Development Expense of Revenue |
292.90% | 368.48% | 399.97% | 226.78% | |
Selling, General and Administrative Expense of Revenue |
97.56% | 129.39% | 151.67% | 83.32% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
35.19% | 45.72% | 43.42% | 36.37% | |
Graham Net Nets |
0.24 | 0.25 | 0.45 | 0.98 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(21.62%) | (21.41%) | (45.25%) | (71.20%) | |
Free Cash Flow Yield |
(17.69%) | (13.99%) | (28.96%) | (62.72%) | |
Revenue per Share |
0.06 | 0.05 | 0.05 | 0.13 | |
Operating CF per Share |
(0.19) | (0.01) | (0.24) | (0.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.19) | (0.01) | (0.24) | (0.27) | |
Cash per Share |
1.51 | 1.94 | 1.87 | 3.00 | |
Shareholders Equity per Share |
1.68 | 1.89 | 1.86 | 3.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.68 | 1.89 | 1.86 | 3.10 | |
Free Cash Flow |
(25.97) | (1.61) | (30.01) | (22.16) | |
Working Capital |
173.04 | 214.66 | 218.12 | 225.08 | |
Capital Expenditures |
— | (0.04) | (0.06) | (0.01) | |
Net Current Asset Value |
110.87 | 150.76 | 150.76 | 155.62 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.62 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.97 | 1.75 | 5.46 | 2.75 | |
Average Payables |
1.15 | 1.67 | 0.73 | 1.09 | |
Average Assets |
298.64 | 327.97 | 324.19 | 354.34 | |
Average Common Equity |
191.29 | 210.66 | 214.69 | 236.29 |
Columns are period end dates · fundamentals updated 5 Nov 2026